Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

被引：199

作者：

Anderson, James R. ^{[1
]}

Cain, Kevin C. ^{[2
]}

Gelber, Richard D. ^{[3
,4
]}

机构：

[1] Univ Nebraska, Coll Publ Hlth, Omaha, NE 68182 USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 24期

关键词：

D O I：

10.1200/JCO.2008.16.1000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3913 / 3915

页数：3

共 20 条

[1] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].

ANDERSON, JR ;

CAIN, KC ;

GELBER, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719

[2] Analysis of outcome by response flawed [J].

Anderson, JR ;

Neuberg, DS .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8122-8123

[3]

ANDERSON JR, 1986, J CLIN ONCOL, V4, P115, DOI 10.1200/JCO.1986.4.1.115

[4]

[Anonymous], 29 ANN SAN ANT BREAS

[5]

BERTINO JR, 1986, J CLIN ONCOL, V4, P1

[6] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].

BONADONNA, G ;

VALAGUSSA, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15

[7] Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients [J].

Bruzzi, P ;

Del Mastro, L ;

Sormani, MP ;

Bastholt, L ;

Danova, M ;

Focan, C ;

Fountzilas, G ;

Paul, J ;

Rosso, R ;

Venturini, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5117-5125

[8] DOSE-RESPONSE IN THE TREATMENT OF BREAST-CANCER - A CRITICAL-REVIEW [J].

HENDERSON, IC ;

HAYES, DF ;

GELMAN, R .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1501-1515

[9] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].

Joensuu, H ;

Kellokumpu-Lehtinen, P ;

Bono, P ;

Alanko, T ;

Kataja, V ;

Asola, R ;

Utriainen, T ;

Kokko, R ;

Hemminki, A ;

Tarkkanen, M ;

Turpeenniemi-Hujanen, T ;

Jyrkkiö, S ;

Flander, M ;

Helle, L ;

Ingalsuo, S ;

Johansson, K ;

Jääskeläinen, A ;

Pajunen, M ;

Rauhala, M ;

Kaleva-Kerola, J ;

Salminen, T ;

Leinonen, M ;

Elomaa, I ;

Isola, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820

[10] Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials [J].

Lara, Primo N., Jr. ;

Redman, Mary W. ;

Kelly, Karen ;

Edelman, Martin J. ;

Williamson, Stephen K. ;

Crowley, John J. ;

Gandara, David R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :463-467

← 1 2 →